Lise Boussemart

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma

Sébastien Corre, Nina Tardif, Nicolas Mouchet et al. · Nature Communications · 2018 · 95 citations · Full text

Medicine, Cancer Biology, Oncology +16

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy

L. Dousset, F. Poizeau, Caroline Robert et al. · JCO Precision Oncology · 2021 · 61 citations · Full text

Medicine, Dermatology, Oncology +17

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)

Charlée Nardin, Aymeric Hennemann, Kadiatou Diallo et al. · Cancers · 2023 · 27 citations · Full text

Medicine, Immunology, Oncology +17

Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies

Alexandra Frelau, Xavier Palard-Novello, E. Jali et al. · Cancer Immunology Immunotherapy · 2020 · 17 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010–2017

F. Poizeau, Sandrine Kerbrat, André Happe et al. · Journal of Investigative Dermatology · 2020 · 17 citations · Full text

Medicine, Oncology, Pharmacology +14